Skip to main content
main-content

28.11.2018 | Original paper

Potential protein markers for breast cancer recurrence: a retrospective cohort study

Zeitschrift:
Cancer Causes & Control
Autoren:
Chunyan He, Rina Plattner, Vivek Rangnekar, Binhua Zhou, Chunming Liu, Rachel L. Stewart, Bin Huang, Chi Wang, Thomas C. Tucker
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s10552-018-1099-8) contains supplementary material, which is available to authorized users.

Abstract

Background

We evaluated five key proteins involved in various cancer-related pathways and assessed their relation to breast cancer recurrence.

Methods

We used the Kentucky Cancer Registry to retrospectively identify primary invasive breast cancer cases (n = 475) that were diagnosed and treated at University of Kentucky Medical Center between 2000 and 2007. Breast cancer recurrence was observed in 62 cases during the 5-year follow-up after diagnosis. Protein expression or activity level was analyzed from surgery tissue using immuno-histochemical assays.

Results

Compared to ER+/PR+/HER2− patients without recurrence, those with recurrence had higher TWIST expression (p = 0.049) but lower ABL1/ABL2 activity (p = 0.003) in primary tumors. We also found that triple-negative breast cancer patients with recurrence had higher SNAI1 expression compared to those without recurrence (p = 0.03). After adjusting for potential confounders, the higher ABL1/ABL2 activity in primary tumors was associated with a decreased risk of recurrence (OR 0.72, 95% CI 0.85–0.90) among ER+/PR+/HER2− patients. In addition, among patients with recurrence we observed that the activity level of ABL1/ABL2 was significantly increased in recurrent tumors compared to the matched primary tumors regardless of the subtype (p = 0.013).

Conclusions

These findings provide evidence that the expression/activity level of various proteins may be differentially associated with risk of recurrence of breast tumor subtypes.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (PDF 125 KB)
10552_2018_1099_MOESM1_ESM.pdf
Supplementary material 2 (PDF 71 KB)
10552_2018_1099_MOESM2_ESM.pdf
Supplementary material 3 (PDF 1640 KB)
10552_2018_1099_MOESM3_ESM.pdf
Supplementary material 4 (DOCX 649 KB)
10552_2018_1099_MOESM4_ESM.docx
Supplementary material 5 (DOCX 16 KB)
10552_2018_1099_MOESM5_ESM.docx
Literatur
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise